Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.
Acute Disease
Disease Progression
Echocardiography
/ methods
Female
Fibrinolytic Agents
/ therapeutic use
Follow-Up Studies
Heart Ventricles
/ diagnostic imaging
Humans
Male
Middle Aged
Pulmonary Embolism
/ diagnosis
Recovery of Function
Retrospective Studies
Risk Factors
Tenecteplase
/ therapeutic use
Thrombolytic Therapy
/ methods
Time Factors
Treatment Outcome
Ventricular Function, Right
/ physiology
Chronic thromboembolic pulmonary hypertension
Post-PE impairment
Pulmonary embolism
Right ventricular dysfunction
Risk stratification
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
06
09
2018
accepted:
10
12
2018
pubmed:
20
12
2018
medline:
18
12
2019
entrez:
20
12
2018
Statut:
ppublish
Résumé
Symptoms and functional limitation are frequently reported by survivors of acute pulmonary embolism (PE). However, current guidelines provide no specific recommendations on which patients should be followed after acute PE, when follow-up should be performed, and which tests it should include. Definition and classification of late PE sequelae are evolving, and their predictors remain to be determined. In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we focused on 219 survivors of acute intermediate-risk PE with clinical and echocardiographic follow-up 6 months after randomisation as well as over the long term (median, 3 years after acute PE). The primary outcome was a composite of (1) confirmed chronic thromboembolic pulmonary hypertension (CTEPH) or (2) 'post-PE impairment' (PPEI), defined by echocardiographic findings indicating an intermediate or high probability of pulmonary hypertension along with New York Heart Association functional class II-IV. Confirmed CTEPH or PPEI occurred in 29 (13.2%) patients, (6 with CTEPH and 23 with PPEI). A history of chronic heart failure at baseline and incomplete or absent recovery of echocardiographic parameters at 6 months predicted CTEPH or PPEI at long-term follow-up. CTEPH or PPEI occurs in almost one out of seven patients after acute intermediate-risk PE. Six-month echocardiographic follow-up may be useful for timely detection of late sequelae.
Identifiants
pubmed: 30564950
doi: 10.1007/s00392-018-1405-1
pii: 10.1007/s00392-018-1405-1
pmc: PMC6584226
doi:
Substances chimiques
Fibrinolytic Agents
0
Tenecteplase
WGD229O42W
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
772-778Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : BMBF 01KG0802, 01EO1003 and 01EO1503
Organisme : Bundesministerium für Bildung und Forschung
ID : BMBF 01EO1003 and 01EO1503
Organisme : Programme Hospitalier de Recherche Clinique
ID : PHRC AOM 03063, AOM 08231 and AOM 10171
Références
Circulation. 1999 Mar 16;99(10):1325-30
pubmed: 10077516
Heart. 2007 Apr;93(4):476-82
pubmed: 17005715
Eur Heart J. 2007 Oct;28(20):2517-24
pubmed: 17670755
Chest. 2010 Dec;138(6):1432-40
pubmed: 20495104
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
Am J Cardiol. 2013 Jan 15;111(2):273-7
pubmed: 23102885
J Thromb Haemost. 2014 Apr;12(4):459-68
pubmed: 24484241
N Engl J Med. 2014 Apr 10;370(15):1402-11
pubmed: 24716681
Thromb Haemost. 2014 Sep 2;112(3):598-605
pubmed: 24898545
Blood Rev. 2014 Nov;28(6):221-6
pubmed: 25168205
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k
pubmed: 25173341
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circulation. 2016 Mar 1;133(9):859-71
pubmed: 26826181
Am J Med. 2016 Sep;129(9):978-985.e2
pubmed: 27046247
J Thromb Thrombolysis. 2016 Nov;42(4):600-9
pubmed: 27577542
Vasc Med. 2017 Feb;22(1):37-43
pubmed: 27707980
Chest. 2017 May;151(5):1058-1068
pubmed: 27932051
Eur Respir J. 2017 Feb 23;49(2):
pubmed: 28232411
J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544
pubmed: 28335835
Am J Med. 2017 Aug;130(8):990.e9-990.e21
pubmed: 28400247
Clin Res Cardiol. 2018 Jul;107(7):548-553
pubmed: 29450722